| Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. | |
| | |
MedLine Citation:
|
PMID: 11730649 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To evaluate the intraocular pressure-lowering efficacy and safety of travoprost 0.0015% and 0.004%, dosed daily in the evening compared with vehicle, in patients with open-angle glaucoma or ocular hypertension, whose intraocular pressure was not adequately controlled on timolol 0.5% twice daily (twice daily). METHODS: Subjects who qualified at screening began a run-in period dosing timolol twice daily for 3 weeks. If the subjects had an intraocular pressure of 24 to 36 mm Hg at 8 AM and 21 to 36 mm Hg at 10 AM and 4 pm in at least one eye on timolol, they were randomized to one of two concentrations of travoprost (0.0015% or 0.004%) or vehicle solution every day and were followed for 6 months. Four hundred twenty-six subjects were randomized. The mean intraocular pressure at 8 AM, 10 AM, and 4 PM in the patient's eye with the higher intraocular pressure was used for the analysis. RESULTS: Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups. The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively. These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg). The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle. Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups. No iris pigmentation changes were observed in any patient during this study. There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups. There were no serious adverse events reported for any treatment group. CONCLUSIONS: Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension. |
| | |
Authors:
|
S Orengo-Nania; T Landry; M Von Tress; L H Silver; A Weiner; A A Davis; |
Related Documents
:
|
7462539 - Respiratory responses to ascaris antigen in rhesus and cynomolgus monkeys. 17922069 - Estimation of intraocular pressure in rabbits using noncontact tonometer: a comparative... 1414289 - Primary argon laser trabeculoplasty vs. pilocarpine. short-term effects. 22703929 - Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth f... 1559769 - Prostaglandin e in rabbit aqueous humor after nd-yag laser photodisruption of iris and ... 8361399 - Direct measurement of retinal microvascular pressures in the live, anesthetized cat. 7017589 - The role of the cardiac nerves in regulation of sodium excretion in conscious dogs. 10896879 - Effects of photoperiod reduction on rat circadian rhythms of bp, heart rate, and locomo... 3131069 - Total parenteral nutrition-induced cyclic hypercapnia. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: American journal of ophthalmology Volume: 132 ISSN: 0002-9394 ISO Abbreviation: Am. J. Ophthalmol. Publication Date: 2001 Dec |
Date Detail:
|
Created Date: 2001-12-03 Completed Date: 2002-01-17 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370500 Medline TA: Am J Ophthalmol Country: United States |
Other Details:
|
Languages: eng Pagination: 860-8 Citation Subset: AIM; IM |
Affiliation:
|
Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, 6565 Fannin, NC-205, Houston, TX 77030, USA. silviao@bcm.tmc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
administration & dosage,
therapeutic use* Aged Aged, 80 and over Antihypertensive Agents / administration & dosage, therapeutic use* Chemotherapy, Adjuvant Cloprostenol / administration & dosage, analogs & derivatives*, therapeutic use* Double-Blind Method Drug Evaluation Drug Therapy, Combination Female Glaucoma, Open-Angle / drug therapy* Humans Intraocular Pressure / drug effects* Male Ocular Hypertension / drug therapy Ophthalmic Solutions Prospective Studies Safety Timolol / administration & dosage, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Ophthalmic Solutions; 157283-68-6/travoprost; 26839-75-8/Timolol; 40665-92-7/Cloprostenol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of retinal vessel caliber and visual field defects in glaucoma.
Next Document: Predictive value of a 1-day, 1-eye trial on the 1-month ocular hypotensive response of latanoprost 0...